Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway
International Journal of Urology · 2024-12 · 31 (12) · 1429-1437
DOI: 10.1111/iju.15576 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 11.09.2024. Verfasst von Junya Hata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Disease Models, Animal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Objectives
The expressions of complement component C5a and NLRP3 inflammasome and the antiproliferative effect of resveratrol in benign prostatic hyperplasia (BPH) model rat were analyzed to clarify the BPH proliferative mechanism.
Methods
This study used the pathological stromal‐dominant BPH model rat by urogenital sinus implantation (UGS). Expression of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 using rat BPH tissues at 2, 3, and 8 weeks ( n = 6, respectively) after UGS implantation were analyzed by qRT‐PCR, western blotting analysis, and immunohistochemical (IHC) analysis. Serum IL‐1β levels in BPH model and sham rats were measured by enzyme‐linked immunosorbent assay. Furthermore, resveratrol, as the NLRP3 pathway inhibitor, was administered to BPH model rat to assess the antiproliferative effect on the BPH proliferative process. The proliferative effect on prostate was evaluated by Ki‐67 protein expression.
Results
The expression levels of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 in qRT‐PCR, western blotting, and IHC were significantly upregulated in BPH tissues compared to control prostate tissues and showed increases with time (all p < 0.05). Serum IL‐1β levels in BPH model rats had significantly increased compared to sham rats. On IHC, deposition of C5a, NLRP3, Caspase‐1, IL‐1β, and IL‐18 was abundant in stromal areas of BPH. The administration of resveratrol significantly decreased prostate weight and expressions of NLRP3, IL‐1β, IL‐18, and Ki‐67 (all p < 0.05).
Conclusions
NLRP3 inflammasome activation by complement C5a produces IL‐1β and IL‐18 through Caspase‐1 during the BPH proliferative process. NLRP3 inflammasome have the possibilities to be a therapeutic target for BPH proliferation by inhibiting the NLRP3 inflammasome pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.
ORCID-Profile: Junya Hata, Kanako Matsuoka, Satoru Meguro, Soichiro Ogawa
Zitieren
APA
Hata, J., Matsuoka, K., Harigane, Y., Yaginuma, K., Akaihata, H., Meguro, S., Honda-Takinami, R., Onagi, A., Sato, Y., Ogawa, S., Uemura, M., & Kojima, Y. (2024). Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway. International Journal of Urology, 31(12), 1429-1437. https://doi.org/10.1111/iju.15576
Vancouver
Hata J, Matsuoka K, Harigane Y, Yaginuma K, Akaihata H, Meguro S, et al. Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway. International Journal of Urology. 2024;31(12):1429-1437. doi:10.1111/iju.15576
BibTeX
@article{Hata2024,
author = {Hata, Junya and Matsuoka, Kanako and Harigane, Yuki and Yaginuma, Kei and Akaihata, Hidenori and Meguro, Satoru and Honda-Takinami, Ruriko and Onagi, Akifumi and Sato, Yuichi and Ogawa, Soichiro and Uemura, Motohide and Kojima, Yoshiyuki},
title = {Proliferative mechanism of benign prostatic hyperplasia by NLRP3 inflammasome through the complement pathway},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {12},
pages = {1429--1437},
doi = {10.1111/iju.15576}
}
EUVIMED